ASX:PNV

PolyNovo (PNV) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
3.38 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
6.86%
Price Target
N/A
PNV stock logo

About PolyNovo Stock (ASX:PNV)

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

PNV Stock News Headlines

The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
PolyNovo Limited (PNV.AX)
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?
Polynovo Ltd (MFJ.SG)
PNV.AX - PolyNovo Limited
See More Headlines
Receive PNV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyNovo and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
237
Year Founded
N/A

Profitability

Net Income
$1.59 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$83.47 million
Book Value
A$0.10 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.65
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Swami Raote BPHARM
    M.B.A., CEO & Director
  • Mr. Jan-Marcel Gielen C.A.
    CFO & Company Secretary
  • Dr. David McQuillan Ph.D.
    Chief Technical & Scientific Officer
  • Mr. Philip Scorgie
    Chief Information Officer
  • Mr. Ahmed Hassan
    Director of Operations
  • Ms. Monica Benyk
    Director of People
  • Dr. Tim Moore
    Principal Scientist
  • Mr. Edward Graubart
    President of North America
  • Dr. Joseph F. Amaral M.D. (Age 68)
    Chief Medical Officer

PNV Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of PolyNovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PolyNovo investors own include Immutep (IMMP), Rural Funds Group (RFF), Vanguard FTSE Pacific ETF (VPL), UQM Technologies (UQM), Tesla (TSLA), Starpharma (SPL), Moelis Australia (MOE), iSignthis (ISX), Align Technology (ALGN) and Acasti Pharma (ACST).

This page (ASX:PNV) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners